26 November 2020
Precision Cancer Diagnostic Test Market Report 2021-2031: Forecasts by Category (Cancer Imaging, Molecular Cancer Testing, Tumour Marker Immunoassays, POC Colon Cancer Tests), by Cancer Imaging Test (Computed Tomography, Magnetic Resonance Imaging, Digital & Analog Mammography, Positron Emission Tomography, Digital Breast Tomosynthesis, Molecular Breast Imaging), by Molecular Cancer Testing (Blood-Based Molecular Cancer Tests, HPV Genotyping, Circulating Tumour Cell (CTC) Tests, Next-Generation Sequencing Tests), by End-user (Hospitals, Clinics, Research Institutes) and Regional and Leading National Market Analysis PLUS Analysis of Leading Precision Cancer Diagnostic Test Companies AND COVID-19 Recovery Scenarios.
Are you curious to know Why Precision Cancer Diagnostics Test Markets is growing and how it could benefit you?
Advanced diagnostics for cancer represent a major market opportunity for life sciences companies. Many cancer types are on the rise as the aging populations of many countries continue to grow. As a result, there is an increasing demand for non-invasive, diagnostic assays that can detect cancers earlier, molecularly subtype tumours to guide therapy decisions and monitor cancer recurrence in treated individuals. According to Visiongain analysis, the global precision cancer diagnostic test market is estimated to be valued at US$xx million in 2020 and is projected to reach at a market value of US$xx million by 2031.
Are significant new product launches propelling the market growth?
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers. New molecular diagnostics can simplify decision-making and reduce uncertainty, but can also complicate treatment selection: multiple tests may be used to identify markers, and their results are likely to vary in specificity and sensitivity. Molecular diagnostics are rapidly transforming drug development and patient selection.
Buy this report to find answers for below questions and how can help you to stay updated
• How much will the precision cancer diagnostic tests industry share grow during the forecast timeline?
• Are Political influence and online misinformation threatening cancer programmes worldwide?
• Is it true that public trust volatile and varying widely between countries?
• How scepticism about the safety of cancer diagnostic test tend to hamper precision cancer diagnostic test Sales Growth?
• Perceptions about cancer diagnostic test are much more volatile than they used to be?
• Are governments Planning to be extra vigilant about assessing public trust in cancer diagnostic test and responding rapidly to concerns?
• Consumers are more keen on thoroughness, effectiveness and safety of precision cancer diagnostic tests than other factors
• How are precision cancer diagnostic tests at diagnostic centres better than that done at hospitals?
Leading Players Profiled in the Report
Agilent Technologies, Inc.
Becton, Dickinson and Company (BD)
Bio-Rad Laboratories, Inc.
Danaher Corporation (Danaher)
Roche Holding AG (Roche)
General Electric Company
Myriad Genetics, Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.